Login
Password
Remember Me:
The 300
For less than the cost of a cup of coffee... you can join a unique group who believe we must push harder for real anti-aging medicine. Read More...
Email Updates!
html
What The Experts Say
Key genetic, molecular, and nutritional discoveries have been made and can now extend human life-span in current and future generations.
Christiaan Leeuwenburgh - Competitor

SENS roundtable 1: Biotechnological foreseeability of SENS Roundtable meeting, Oakland, October 1st 2000

Article Details/Transcript

This meeting was designed to continue and build upon UCLA's pioneering "roundtable on aging" convened by Gregory Stock in February, 1999. Like the earlier meeting, it included only about ten participants and had a roundtable format with no formal presentations. The major departure from the 1999 meeting was that the focus was somewhat more narrowly defined, as befits a one-day event. We discussed an aspect of biogerontology research that has been dangerously neglected during the recent spate of interest in genome-related breakthroughs: the active reversal of various aspects of age-related degeneration. This is, more-or-less by definition, an area that cannot be informed by comparative analyses between organisms with different rates of aging, which is the focus of microarray and related studies. We do not belittle the value of comparative work, but we feel that far more attention needs to be drawn to ongoing research with the potential to influence human life histories more dramatically than anything based purely on emulating other organisms.

The term "negligible senescence", defined in 1990 by Finch, describes the life history of organisms whose risk of death does not measurably rise as they get older, but remains the same as when they reached adulthood. Thus, "engineered negligible senescence" means restoring and maintaining, by biotechnological intervention, the health (and consequent resistance to life-threatening diseases) that we possessed in early adulthood.

We regard engineered negligible senescence as the true objective of biogerontology research. This is in contrast to the view of many gerontologists, who prefer to stress "successful aging" as their goal. "Successful aging" means extending healthy life (healthspan) so that the period of ill health at the end of life (frailty-span) is very short, but without substantially increasing maximum total lifespan, since they consider that unrealistic. Our view is that not only is extending maximum lifespan realistic, it is the only realistic way to shorten frailty-span much beyond present levels, because it entails extending healthspan (and thus postponing frailty) indefinitely.

The Methuselah Foundation is a charitable 501(c)(3) organization; its IRS tax identification number is 54-2040344.
Mprize and Methuselah Foundation are registered trademarks of the Methuselah Foundation.
PO Box 1143, Lorton, VA, 22079-1143, Ph. (202) 306-0989
main@methuselahfoundation.org
Clicky Web Analytics